Neuropace, Inc. (NPCE) has disclosed a new risk, in the Technology category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuropace, Inc. faces heightened cybersecurity and IT resilience risk because its operations, including manufacturing, distribution and clinical data workflows, depend on complex, interconnected systems and third-party technologies. Any breach, ransomware event or prolonged outage could disrupt product availability, compromise sensitive health and financial data and trigger regulatory, legal and remediation costs.
Given the sensitivity of intracranial EEG data and other patient information processed through its RNS System, remote access tools and cloud services, Neuropace is particularly exposed to reputational damage and loss of clinician and patient trust if security incidents occur. Increasingly sophisticated threats, including nation-state attacks, supply-chain compromises and AI-related data leakage, raise the likelihood that existing controls and insurance coverage may prove insufficient, with potential material adverse effects on growth and financial performance.
Overall, Wall Street has a Strong Buy consensus rating on NPCE stock based on 4 Buys.
To learn more about Neuropace, Inc.’s risk factors, click here.